+39.8%
BKNG vs MRNA
+27.9%
+11.9%
-33.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | +0.7% | -0.2% | +0.5% |
| 7D | -10.7% | -8.2% | -2.4% | -10.4% |
| 30D | -18.1% | +125.6% | -143.7% | -22.1% |
| 3M | +8.5% | +197.1% | -188.5% | +0.8% |
| 6M | -0.1% | +148.5% | -148.5% | -6.1% |
| YTD | -18.2% | +363.3% | -381.5% | -27.4% |
| 1Y | -19.9% | +462.0% | -481.9% | -30.3% |
| All | +39.8% | +27.9% | +11.9% | +32.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling